Rapid Micro Biosystems (RPID) AI Stock Analysis

• Market Cap: $137.05M
• Dividend Yield: N/A
• Average Volume (3M): 87.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 16.63%
• EPS Growth: 10.43%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 39,710,800
• 10 Day Avg. Volume: 85,038
• 30 Day Avg. Volume: 87,493
• PEG Ratio: 0.07
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 23.72
• Enterprise Value/Ebitda: -3.12
• 1Y Price Target: $8.00
• Price Target Upside: 146.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $3.00 ▼(-7.41% Downside)

Rapid Micro Biosystems' overall stock score reflects strong revenue growth and positive momentum from recent earnings, but is weighed down by ongoing profitability challenges and negative valuation metrics. The company's strategic initiatives and collaborations offer potential for future improvement.

Positive Factors

Revenue Growth

Consistent revenue growth over multiple quarters highlights the company's ability to expand its market presence and drive sales, indicating a strong demand for its products and services.

Recurring Revenue Model

The growth in consumables and recurring revenue supports a stable income stream, enhancing financial predictability and resilience against market fluctuations.

Strategic Partnerships

Strategic partnerships can lead to cost efficiencies and expanded market reach, strengthening the company's competitive position and long-term profitability.

Negative Factors

Negative Product Margins

Persistently negative product margins indicate challenges in cost management, which can hinder profitability and limit reinvestment opportunities.

Net Losses

Ongoing net losses reflect operational inefficiencies and financial strain, which could impact the company's ability to invest in growth and innovation.

Cash Flow Challenges

Negative cash flows limit the company's ability to fund operations and growth initiatives, potentially leading to increased reliance on external financing.

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems (RPID) is a biotechnology company focused on advancing microbial quality control solutions for the pharmaceutical, biotechnology, and personal care industries. The company specializes in innovative technologies that streamline microbial testing processes, primarily through its Growth Direct System, which allows for rapid and automated detection of microbial contamination in products and environments. RPID aims to enhance quality assurance processes, reduce time to market, and improve product safety for its clients.

How the Company Makes Money

Rapid Micro Biosystems generates revenue through the sale of its Growth Direct System and related consumables, including proprietary growth media and software. The company operates on a recurring revenue model, benefiting from ongoing sales of consumables and maintenance services. Additionally, RPID partners with various pharmaceutical and biotech companies to provide customized solutions, which can lead to lucrative long-term contracts. The expansion of its customer base and the growing demand for rapid microbial testing in regulated industries contribute significantly to its earnings.

Rapid Micro Biosystems Financial Statement Overview

Summary

Rapid Micro Biosystems shows strong revenue growth but struggles with profitability and cash flow. The company has increased leverage, which could pose risks if not managed carefully. Improvements in gross profit margins and free cash flow growth are positive, but negative net income and operating cash flow highlight the need for better cost management.

Income Statement

Rapid Micro Biosystems shows a significant revenue growth rate of 77.3% in the TTM, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative margins across the board, including a net profit margin of -145.11% and an EBIT margin of -109.20%. The gross profit margin has improved to 24.18% in the TTM from negative figures in previous years, but the overall profitability remains a concern.

Balance Sheet

The company's debt-to-equity ratio has increased to 0.54 in the TTM from lower levels in previous years, indicating a rise in leverage. The return on equity remains negative at -73.91%, reflecting ongoing losses. However, the equity ratio is relatively stable, suggesting a solid equity base compared to total assets.

Cash Flow

The cash flow statement reveals a positive free cash flow growth rate of 78.6% in the TTM, but the operating cash flow remains negative. The operating cash flow to net income ratio is -2.25, indicating cash flow challenges. Despite these issues, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.52M	28.05M	22.52M	17.13M	23.23M	16.08M
Gross Profit	5.61M	-109.00K	-5.49M	-8.54M	-7.74M	-8.07M
EBITDA	-42.58M	-46.56M	-53.46M	-60.38M	-45.70M	-32.00M
Net Income	-44.29M	-46.89M	-52.47M	-60.81M	-73.52M	-37.08M
Balance Sheet
Total Assets	84.41M	98.17M	143.45M	190.65M	241.17M	70.00M
Cash, Cash Equivalents and Short-Term Investments	41.25M	50.73M	92.05M	108.65M	193.50M	45.08M
Total Debt	24.11M	6.17M	7.35M	7.97M	0.00	24.81M
Total Liabilities	40.08M	22.82M	25.46M	26.48M	20.19M	45.18M
Stockholders Equity	44.33M	75.35M	117.99M	164.17M	220.98M	24.82M
Cash Flow
Free Cash Flow	-38.58M	-45.52M	-46.93M	-65.29M	-58.18M	-31.69M
Operating Cash Flow	-37.73M	-44.15M	-45.08M	-58.55M	-54.96M	-31.00M
Investing Cash Flow	15.30M	36.66M	42.15M	-93.47M	-13.29M	-15.67M
Financing Cash Flow	19.32M	203.00K	149.00K	693.00K	216.75M	64.23M

Rapid Micro Biosystems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Positive. The current price of 3.24 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 3.08, and above the 200-day MA of 2.96, indicating a bullish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 68.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPID.

Rapid Micro Biosystems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGHT	54 Neutral	$260.79M	-5.19	-57.91%	―	-4.39%	11.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RPID	51 Neutral	$137.05M	―	-68.83%	―	16.63%	10.43%
LUCD	48 Neutral	$148.21M	―	-463.56%	―	14.74%	14.63%
HYPR	47 Neutral	$96.28M	-1.97	-77.26%	―	-9.59%	8.78%
LUNG	46 Neutral	$70.08M	-1.20	-66.88%	―	18.24%	4.81%
LNSR	38 Underperform	$145.13M	―	-422.35%	―	21.02%	-200.88%

Rapid Micro Biosystems Corporate Events

Rapid Micro Biosystems Reports Q3 Growth and Raises Guidance

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company that provides automation solutions for efficient manufacturing and safe release of healthcare products, primarily operating in the pharmaceutical sector. In its third quarter of 2025, the company reported a total revenue of $7.8 million, marking a 3% increase from the previous year, with a notable 32% rise in recurring revenue driven by record consumable sales. The company also announced a significant multi-system order from a top global biopharma customer, which is expected to enhance its growth trajectory. Key financial highlights include a gross margin improvement to 9%, a reduction in operating expenses by 5%, and a net loss of $11.5 million, consistent with the previous year. Looking ahead, Rapid Micro Biosystems has raised its full-year revenue guidance to at least $33 million, anticipating substantial contributions from its recent customer order and continued adoption of its Growth Direct platform.

Rapid Micro Biosystems Earnings Call: Growth Amid Challenges

The recent earnings call of Rapid Micro Biosystems, Inc. Class A painted a mixed picture of the company’s current financial health and future prospects. While the call highlighted significant revenue growth and strategic advancements, including a new loan facility and progress in partnerships, it also acknowledged challenges with product margins and ongoing market uncertainties affecting system placements.

Rapid Micro Biosystems Reports Revenue Growth in Q2 2025

Rapid Micro Biosystems, Inc. is a life sciences technology company that provides automation solutions for microbial quality control in pharmaceutical manufacturing, enhancing the efficiency and safety of healthcare product releases. In its second quarter of 2025 financial report, the company announced a 10% increase in total revenue, reaching $7.3 million, compared to the same period in 2024. This growth was driven by an 18% increase in service revenue and a 6% rise in product revenue.

Rapid Micro Biosystems Secures $45M Loan for Growth

On August 8, 2025, Rapid Micro Biosystems entered into a Loan and Security Agreement with Trinity Capital Inc., securing a $45 million term loan facility to bolster its financial position and support long-term growth. The company reported a 10% increase in total revenue for the second quarter of 2025 compared to the previous year, driven by strong performance in service and product revenue, and reaffirmed its full-year revenue guidance of at least $32 million.

The most recent analyst rating on (RPID) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.